Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Colorectal cancer is a major oncological problem. The rate of cancer growth depends on proliferative activity and tumor cell death rate. Therefore, the study objective was to estimate the expression of Bcl-2 as an apoptotic protein representative, as well as other proteins involved in proliferation PCNA (proliferating cell nuclear antigen), Ki-67 and MCM-2 (minichromosome maintaince), and to analyze the correlations between them and chosen anatomo-clinical parameters.
Materials And Methods: The expressions of these proteins were analyzed in 47 patients with pT3, G2 colorectal cancer by immunohistochemistry.
Results: No association was found between the expressions of Bcl-2, PCNA, Ki-67, MCM-2 and histological type of tumor, distant metastasis, gender or age of patients. However, we observed a correlation of PCNA, Ki-67 and MCM-2 expressions, but not of Bcl-2, in the main mass of tumor in patients with lymph node metastases. Moreover, a very strong relationship was noted between the expression of Bcl-2 and PCNA, Ki-67 and MCM-2 in the main mass of tumor. Conlusion: These investigations seem to suggest that the expression of proliferative proteins (PCNA, Ki-67, MCM-2) in pT3, G2 of colorectal cancer may indicate the development of lymph node metastases and that inhibited apoptosis by Bcl-2 protein can enhance the action of these proteins in tumor progression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Integrating Mcm-2 and Ki-67 immunohistochemistry with clinico-pathologic parameters for enhanced prognostic accuracy in oral verrucous lesions.
J Stomatol Oral Maxillofac Surg
March 2025
Department of Oral and Maxillofacial Pathology, College Of Dental Sciences, Davangere, Karnataka 577004, India.
Article Synopsis
- Oral verrucous lesions (OVLs) are challenging to diagnose due to varying histopathological features, and this study investigates Mcm-2 and Ki-67 as markers to help differentiate these lesions from oral squamous cell carcinoma (OSCC).
- Using 90 paraffin-embedded tissue samples, the researchers assessed the expression levels of Mcm-2 and Ki-67, alongside patient survival data, employing statistical methods for analysis.
- Findings revealed that Mcm-2 is a more sensitive and prognostic indicator than Ki-67, with higher overexpression in verrucous lesions and improved survival rates in verrucous squamous cell carcinoma (VSCC) compared to conventional OSCC, suggesting its potential for better diagnosis
Expression analysis of cyclin D, Ki-67, MCM3 and MCM2 in oral squamous cell carcinoma.
Bioinformation
December 2023
Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia.
The expression analysis of cyclin D1, Ki-67, MCM3 and MCM2 in oral squamous cell carcinoma to identify biomarkers is of interest. 45 formalin-fixed paraffin embedded tissue blocks collected from archives of Department of Oral and Maxillofacial Pathology and Oral Microbiology, Government Dental College and Hospital, Jamnagar, India were subjected to a retrospective cross-sectional immuno-histo-chemistry examination. 30 blocks of OSCC with histological diagnosis have 15 tissue blocks of well-differentiated oral carcinoma and 15 tissue blocks of moderately-differentiated oral carcinoma.
View Article and Find Full Text PDFMCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
Breast Cancer (Dove Med Press)
September 2023
Department of General Surgery, Istanbul University Istanbul School of Medicine, İstanbul, Turkey.
Background: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and determine an MCM-2 cutoff value in high-risk patients according to TAILORx risk categorization.
Methods: Hormone receptor (HR) positive HER-2 negative early-stage breast cancer patients (pT1-2, pN0-N1, M0) who had ODX-RS were included in the study.
MCM-2, Ki-67, and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma.
Sci Rep
July 2021
Department of Physiology, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Patumwan, Bangkok, 10330, Thailand.
We present the conceptual study investigated the capacity of minichromosome maintenance-2 (MCM-2), Ki-67, and epidermal growth factor receptor (EGFR) to assess the severity and progression of laryngeal squamous cell carcinoma (LSCC) disease and to study the correlations among these markers. A total of 30 patients with LSCC with immunohistochemistry (IHC) staining for MCM-2, Ki-67 and EGFR were examined. Mean expression levels of the three markers were evaluated for comparing between early and advanced stages of LSCC.
View Article and Find Full Text PDFMCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.
Neoplasia
October 2019
Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada H3T 1J4. Electronic address:
Breast cancer is a heterogeneous disease comprising the estrogen receptor (ER)-positive luminal subtype which is subdivided into luminal A and luminal B and ER-negative breast cancer which includes the triple-negative subtype. This study has four aims: 1) to examine whether Minichromosome Maintenance (MCM)2, MCM4, and MCM6 can be used as markers to differentiate between luminal A and luminal B subtypes; 2) to study whether MCM2, MCM4, and MCM6 are highly expressed in triple-negative breast cancer, as there is an urgent need to search for surrogate markers in this aggressive subtype, for drug development purposes; 3) to compare the prognostic values of these markers in predicting relapse-free survival; and 4) to compare the three approaches used for scoring the protein expression of these markers by immunohistochemistry (IHC). MCM2, MCM4, MCM6, and MKI67 mRNA expression was first studied using in silico analysis of available breast cancer datasets.
View Article and Find Full Text PDF